← Oncology Approval Tracker

FDA DECISION ·

Zejula

niraparib · GlaxoSmithKline

FDA approvalNew or expanded indicationOvarian, fallopian tube and primary peritoneal cancers
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Maintenance therapy for adults with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer in complete or partial response to first-line platinum-based chemotherapy. The original decision had no biomarker requirement.

LAMPGEN ANALYSIS

Why it matters

Brought PARP inhibitor maintenance into first-line care for platinum responders under the original label.

What research teams should watch

Record platinum response and baseline blood counts and weight for dose selection and monitoring.

PRIMARY RECORDS

Sources